查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全EXOME定序的全球市場 - 產業趨勢和至2029年的預測
市場調查報告書
商品編碼
1100166

全EXOME定序的全球市場 - 產業趨勢和至2029年的預測

Global Whole Exome Sequencing Market - Industry Trends and Forecast to 2029
出版日期: | 出版商: Data Bridge Market Research | 英文 320 Pages | 商品交期: 請詢問到貨日

價格

全球全EXOME定序的市場規模，預計在2022年～2029年的預測期間中以19.0％大幅度的年複合成長率擴大。

本報告提供全球全EXOME定序市場相關調查，市場概要，以及各零件，各產品、服務，各用途，各終端用戶，各流通管道，各地區的趨勢，及加入此市場的主要企業的簡介等資訊。

目錄

第1章 簡介

第2章 市場區隔

第3章 摘要整理

第4章 重要考察

第5章 全球全EXOME定序市場:法規

第6章 市場概要

  • 促進因素
  • 阻礙因素
  • 機會
  • 課題

第7章 全球全EXOME定序市場，各零件

  • 概要
  • 第2代的定序
  • 第3代定序

第8章 全球全EXOME定序市場，各產品、服務

  • 概要
  • 系統
  • 套件
  • 服務

第9章 全球全EXOME定序市場，各用途

  • 概要
  • 藥物研發、開發
  • 農業、動物研究
  • 診斷
  • 個人化醫療
  • 其他

第10章 全球全EXOME定序市場，各終端用戶

  • 概要
  • 製藥公司及生物科技企業
  • 學術研究機關
  • 醫院、診所
  • 臨床檢驗室
  • 其他

第11章 全球全EXOME定序市場，各流通管道

  • 概要
  • 直接交易
  • 零售
  • 其他

第12章 全球全EXOME定序市場，各地區

  • 概要
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東、非洲

第13章 全球全EXOME定序市場:企業形勢

第14章 企業簡介

  • PERKINELMER GENOMICS
  • MERCK KGAA
  • EXODX
  • THERMO FISHER SCIENTIFIC INC.
  • FOUNDATION MEDICINE, INC.
  • AZENTA US, INC.
  • BECKMAN COULTER, INC
  • BIONEER CORPORATION
  • CD GENOMICS
  • CEGAT GMBH
  • EUROFINS SCIENTIFIC
  • GENEDX, LLC
  • GENEFIRST LIMITED.
  • ILLUMINA, INC
  • INTEGRATED DNA TECHNOLOGIES, INC.
  • MERIDIAN BIOSCIENCE, INC.
  • PSOMAGEN
  • QIAGEN
  • SOPHIA GENETICS
  • TWIST BIOSCIENCE

第15章 問卷調查

第16章 相關報告

Global whole exome sequencing (WES) market is projected to register a substantial CAGR of 19.0% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2022 to 2029.

Market Segmentation:

Whole Exome Sequencing (WES) Market, By Component (Second generation sequencing and Third-Generation sequencing), Product and Service (systems, kits and services), Application (Drug discovery and development, agriculture & animal research, diagnostics, personalized medicine and others ), End User (pharmaceutical & biotechnology companies, academic & research institutes, hospitals, clinical laboratories and others), Distribution Channel (direct trade, retail sales and others), Industry Trends and Forecast to 2029.

Global whole exome sequencing (WES) market is categorized into four notable segment which is Component, Product and Service, Application, End User and Distribution Channel.

On the basis of component, the global whole exome sequencing (WES) market is segmented into second generation sequencing and third-generation sequencing.

On the basis of Product and Service, the global whole exome sequencing (WES) market is segmented into systems, kits and services.

On the basis of Application, the global whole exome sequencing (WES) market is segmented into drug discovery and development, agriculture & animal research, diagnostics, personalized medicine and others.

On the basis of End user, the global whole exome sequencing (WES) market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, hospitals, clinical laboratories and others.

On the basis of Distribution Channel, the global whole exome sequencing (WES) market is segmented into direct trade, retail sales and others.

Some of the major factors contributing to the growth of the global Whole Exome Sequencing (WES) market are:

  • Increase in the adoption of whole exome sequencing (WES)
  • Growing usage of targeted sequencing methods

Market Players:

The key market players for global whole exome sequencing (WES) market are listed below:

  • Thermo Fisher Scientific Inc.
  • QIAGEN
  • Illumina, Inc.
  • Beckman Coulter, Inc.
  • Eurofins Scientific
  • BIONEER CORPORATION
  • ExoDx (a part of Bio-Techne)
  • FOUNDATION MEDICINE, INC. (A subsidiary of F. Hoffmann-La Roche Ltd)
  • GeneFirst Limited
  • CeGaT GmbH
  • Meridian
  • Merck KGaA
  • SOPHiA GENETICS
  • Azenta U.S. Inc.
  • CD Genomics
  • Twist Bioscience
  • PerkinElmer Genomics (A Subsidiary of PerkinElmer Inc.)
  • GeneDx, LLC
  • Psomagen
  • Integrated DNA Technologies, Inc., among others.

TABLE OF CONTENTS

1 INTRODUCTION 34

  • 1.1 OBJECTIVES OF THE STUDY 34
  • 1.2 MARKET DEFINITION 34
  • 1.3 OVERVIEW OF GLOBAL WHOLE EXOME SEQUENCING (WES) MARKET 34
  • 1.4 CURRENCY AND PRICING 36
  • 1.5 LIMITATIONS 36
  • 1.6 MARKETS COVERED 37

2 MARKET SEGMENTATION 40

  • 2.1 MARKETS COVERED 40
  • 2.2 GEOGRAPHICAL SCOPE 41
  • 2.3 YEARS CONSIDERED FOR THE STUDY 42
  • 2.4 DBMR TRIPOD DATA VALIDATION MODEL 43
  • 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 46
  • 2.6 MULTIVARIATE MODELLING 47
  • 2.7 MARKET APPLICATION COVERAGE GRID 48
  • 2.8 PRODUCT TYPE LIFELINE CURVE 49
  • 2.9 DBMR MARKET POSITION GRID 50
  • 2.10 VENDOR SHARE ANALYSIS 52
  • 2.11 SECONDARY SOURCES 53
  • 2.12 ASSUMPTIONS 53

3 EXECUTIVE SUMMARY 54

4 PREMIUM INSIGHT 58

  • 4.1 PORTER'S FIVE FORCES 59
  • 4.2 PESTEL ANALYSIS 60
  • 4.3 INDUSTRIAL INSIGHTS: 61
  • 4.4 CONCLUSION 62

5 GLOBAL WHOLE EXOME SEQUENCING MARKET: REGULATIONS 63

6 MARKET OVERVIEW 65

  • 6.1 DRIVERS 67
    • 6.1.1 GROWING USAGE OF TARGETED SEQUENCING METHODS 67
    • 6.1.2 INCREASE IN THE ADOPTION OF NEXT GENERATION SEQUENCING 67
    • 6.1.3 INCREASING DIAGNOSTICS APPLICATIONS OF WHOLE EXOME SEQUENCING 67
    • 6.1.4 INCREASE TREND TOWARD PERSONALIZED MEDICATION 68

 

  • 6.2 RESTRAINTS 69
    • 6.2.1 LESS COMPREHENSIVE COVERAGE OF EXONS 69
    • 6.2.2 CYBER SECURITY CONCERNS IN GENOMICS 69
  • 6.3 OPPORTUNITIES 70
    • 6.3.1 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYER 70
    • 6.3.2 INCREASING PRODUCT LAUNCHES IN RECENT YEARS 70
  • 6.4 CHALLENGES 71
    • 6.4.1 LACK OF SKILLED PROFESSIONALS 71
    • 6.4.2 ETHICAL AND LEGAL ISSUES RELATED TO WHOLE EXOME SEQUENCING 71

7 GLOBAL WHOLE EXOME SEQUENCING MARKET, BY COMPONENT 72

  • 7.1 OVERVIEW 73
  • 7.2 SECOND-GENERATION SEQUENCING 76
    • 7.2.1 SEQUENCING BY SYNTHESIS (SBS) 77
    • 7.2.2 SEQUENCING BY HYBRIDIZATION (SBH) AND SEQUENCING BY LIGATION (SBL) 77
  • 7.3 THIRD-GENERATION SEQUENCING 78

8 GLOBAL WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE 79

  • 8.1 OVERVIEW 80
  • 8.2 SYSTEMS 83
    • 8.2.1 HISEQ SERIES 84
      • 8.2.1.1 HISEQ 2500 84
      • 8.2.1.2 HISEQ 1500 84
    • 8.2.2 MISEQ SERIES 84
    • 8.2.3 ION TORRENT PLATFORMS 85
      • 8.2.3.1 ION PROTON 85
      • 8.2.3.2 ION PGM 85
    • 8.2.4 OTHERS 85
  • 8.3 KITS 85
    • 8.3.1 DNA FRAGMENTATION, END REPAIR, A-TAILING, AND SIZE SELECTION KITS 86
    • 8.3.2 LIBRARY PREPARATION KITS 86
    • 8.3.3 TARGET ENRICHMENT KITS 87
    • 8.3.4 OTHERS 87
  • 8.4 SERVICES 87
    • 8.4.1 SEQUENCING SERVICES 88
    • 8.4.2 DATA ANALYSIS (BIOINFORMATICS) SERVICES 88
    • 8.4.3 OTHERS 88

 

9 GLOBAL WHOLE EXOME SEQUENCING MARKET, BY APPLICATION 89

  • 9.1 OVERVIEW 90
  • 9.2 DRUG DISCOVERY AND DEVELOPMENT 93
  • 9.3 AGRICULTURE & ANIMAL RESEARCH 94
  • 9.4 DIAGNOSTICS 94
  • 9.5 PERSONALIZED MEDICINE 95
  • 9.6 OTHERS 96

10 GLOBAL WHOLE EXOME SEQUENCING MARKET, BY END USER 97

  • 10.1 OVERVIEW 98
  • 10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 101
  • 10.3 ACADEMIC & RESEARCH INSTITUTES 102
  • 10.4 HOSPITALS AND CLINICS 102
  • 10.5 CLINICAL LABORATORIES 103
  • 10.6 OTHERS 104

11 GLOBAL WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL 105

  • 11.1 OVERVIEW 106
  • 11.2 DIRECT TRADE 109
  • 11.3 RETAIL SALES 109
  • 11.4 OTHERS 111

12 GLOBAL WHOLE EXOME SEQUENCING MARKET, BY REGION 112

  • 12.1 OVERVIEW 113
  • 12.2 NORTH AMERICA 118
    • 12.2.1 U.S. 126
    • 12.2.2 CANADA 129
    • 12.2.3 MEXICO 132
  • 12.3 EUROPE 135
    • 12.3.1 GERMANY 143
    • 12.3.2 FRANCE 147
    • 12.3.3 U.K. 150
    • 12.3.4 RUSSIA 154
    • 12.3.5 ITALY 157
    • 12.3.6 SPAIN 160
    • 12.3.7 TURKEY 163
    • 12.3.8 NETHERLANDS 166
    • 12.3.9 SWITZERLAND 170
    • 12.3.10 BELGIUM 174
    • 12.3.11 REST OF EUROPE 178
  • 12.4 ASIA-PACIFIC 179
    • 12.4.1 CHINA 187
    • 12.4.2 JAPAN 190
    • 12.4.3 INDIA 193
    • 12.4.4 SOUTH KOREA 196
    • 12.4.5 AUSTRALIA 200
    • 12.4.6 SINGAPORE 204
    • 12.4.7 THAILAND 208
    • 12.4.8 INDONESIA 212
    • 12.4.9 PHILIPPINES 216
    • 12.4.10 MALAYSIA 220
    • 12.4.11 VIETNAM 224
    • 12.4.12 REST OF ASIA-PACIFIC 228
  • 12.5 SOUTH AMERICA 229
    • 12.5.1 BRAZIL 237
    • 12.5.2 ARGENTINA 240
    • 12.5.3 REST OF SOUTH AMERICA 244
  • 12.6 MIDDLE EAST AND AFRICA 245
    • 12.6.1 SOUTH AFRICA 253
    • 12.6.2 SAUDI ARABIA 257
    • 12.6.3 U.A.E 261
    • 12.6.4 ISRAEL 264
    • 12.6.5 EGYPT 267
    • 12.6.6 REST OF MIDDLE EAST AND AFRICA 270

13 GLOBAL WHOLE EXOME SEQUENCING MARKET: COMPANY LANDSCAPE 271

  • 13.1 COMPANY SHARE ANALYSIS: GLOBAL 271
  • 13.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 272
  • 13.3 COMPANY SHARE ANALYSIS: EUROPE 273
  • 13.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 274

14 COMPANY PROFILE 275

  • 14.1 PERKINELMER GENOMICS (A SUBSIDIARY OF PERKINELMER INC.) 275
    • 14.1.1 COMPANY SNAPSHOT 275
    • 14.1.2 REVENUE ANALYSIS 275
    • 14.1.3 COM PANY SHARE ANALYSIS 276
    • 14.1.4 PRODUCT PORTFOLIO 276
    • 14.1.5 RECENT DEVELOPMENTS 276

 

  • 14.2 MERCK KGAA 278
    • 14.2.1 COMPANY SNAPSHOT 278
    • 14.2.2 REVENUE ANALYSIS 278
    • 14.2.3 COM PANY SHARE ANALYSIS 279
    • 14.2.4 PRODUCT PORTFOLIO 279
    • 14.2.5 RECENT DEVELOPMENTS 279
  • 14.3 EXODX (A PART OF BIO-TECHNE) 280
    • 14.3.1 COMPANY SNAPSHOT 280
    • 14.3.2 REVENUE ANALYSIS 280
    • 14.3.3 COM PANY SHARE ANALYSIS 281
    • 14.3.4 PRODUCT PORTFOLIO 281
    • 14.3.5 RECENT DEVELOPMENTS 281
  • 14.4 THERMO FISHER SCIENTIFIC INC. 282
    • 14.4.1 COMPANY SNAPSHOT 282
    • 14.4.2 REVENUE ANALYSIS 282
    • 14.4.3 COM PANY SHARE ANALYSIS 283
    • 14.4.4 PRODUCT PORTFOLIO 283
    • 14.4.5 RECENT DEVELOPMENTS 283
  • 14.5 FOUNDATION MEDICINE, INC. (A SUBSIDIARY OF F. HOFFMANN-LA ROCHE LTD) 284
    • 14.5.1 COMPANY SNAPSHOT 284
    • 14.5.2 REVENUE ANALYSIS 284
    • 14.5.3 COM PANY SHARE ANALYSIS 285
    • 14.5.4 PRODUCT PORTFOLIO 285
    • 14.5.5 RECENT DEVELOPMENTS 285
  • 14.6 AZENTA US, INC. 287
    • 14.6.1 COMPANY SNAPSHOT 287
    • 14.6.2 PRODUCT PORTFOLIO 287
    • 14.6.3 RECENT DEVELOPMENTS 287
  • 14.7 BECKMAN COULTER, INC 289
    • 14.7.1 COMPANY SNAPSHOT 289
    • 14.7.2 REVENUE ANALYSIS 289
    • 14.7.3 PRODUCT PORTFOLIO 290
    • 14.7.4 RECENT DEVELOPMENTS 290
  • 14.8 BIONEER CORPORATION 291
    • 14.8.1 COMPANY SNAPSHOT 291
    • 14.8.2 REVENUE ANALYSIS 291
    • 14.8.3 PRODUCT PORTFOLIO 292
    • 14.8.4 RECENT DEVELOPMENTS 292

 

  • 14.9 CD GENOMICS 293
    • 14.9.1 COMPANY SNAPSHOT 293
    • 14.9.2 PRODUCT PORTFOLIO 293
    • 14.9.3 RECENT DEVELOPMENTS 293
  • 14.10 CEGAT GMBH 294
    • 14.10.1 COMPANY SNAPSHOT 294
    • 14.10.2 PRODUCT PORTFOLIO 294
    • 14.10.3 RECENT DEVELOPMENTS 294
  • 14.11 EUROFINS SCIENTIFIC 295
    • 14.11.1 COMPANY SNAPSHOT 295
    • 14.11.2 REVENUE ANALYSIS 295
    • 14.11.3 PRODUCT PORTFOLIO 296
    • 14.11.4 RECENT DEVELOPMENTS 296
  • 14.12 GENEDX, LLC 297
    • 14.12.1 COMPANY SNAPSHOT 297
    • 14.12.2 PRODUCT PORTFOLIO 297
    • 14.12.3 RECENT DEVELOPMENTS 297
  • 14.13 GENEFIRST LIMITED. 299
    • 14.13.1 COMPANY SNAPSHOT 299
    • 14.13.2 PRODUCT PORTFOLIO 299
    • 14.13.3 RECENT DEVELOPMENTS 299
  • 14.14 ILLUMINA, INC 301
    • 14.14.1 COMPANY SNAPSHOT 301
    • 14.14.2 REVENUE ANALYSIS 301
    • 14.14.3 PRODUCT PORTFOLIO 302
    • 14.14.4 RECENT DEVELOPMENTS 302
  • 14.15 INTEGRATED DNA TECHNOLOGIES, INC. 304
    • 14.15.1 COMPANY SNAPSHOT 304
    • 14.15.2 PRODUCT PORTFOLIO 304
    • 14.15.3 RECENT DEVELOPMENTS 304
  • 14.16 MERIDIAN BIOSCIENCE, INC. 306
    • 14.16.1 COMPANY SNAPSHOT 306
    • 14.16.2 REVENUE ANALYSIS 306
    • 14.16.3 PRODUCT PORTFOLIO 307
    • 14.16.4 RECENT DEVELOPMENTS 307
  • 14.17 PSOMAGEN 308
    • 14.17.1 COMPANY SNAPSHOT 308
    • 14.17.2 REVENUE ANALYSIS 308
    • 14.17.3 PRODUCT PORTFOLIO 308
    • 14.17.4 RECENT DEVELOPMENTS 309
  • 14.18 QIAGEN 310
    • 14.18.1 COMPANY SNAPSHOT 310
    • 14.18.2 REVENUE ANALYSIS 310
    • 14.18.3 PRODUCT PORTFOLIO 311
    • 14.18.4 RECENT DEVELOPMENTS 311
  • 14.19 SOPHIA GENETICS 312
    • 14.19.1 COMPANY SNAPSHOT 312
    • 14.19.2 REVENUE ANALYSIS 312
    • 14.19.3 PRODUCT PORTFOLIO 313
    • 14.19.4 RECENT DEVELOPMENTS 313
  • 14.20 TWIST BIOSCIENCE 314
    • 14.20.1 COMPANY SNAPSHOT 314
    • 14.20.2 REVENUE ANALYSIS 314
    • 14.20.3 PRODUCT PORTFOLIO 315
    • 14.20.4 RECENT DEVELOPMENTS 315

15 QUESTIONNAIRE 317

16 RELATED REPORTS 320

LIST OF FIGURES

  • FIGURE 1 GLOBAL WHOLE EXOME SEQUENCING (WES) MARKET: SEGMENTATION 40
  • FIGURE 2 GLOBAL WHOLE EXOME SEQUENCING (WES) MARKET: DATA TRIANGULATION 43
  • FIGURE 3 GLOBAL WHOLE EXOME SEQUENCING (WES) MARKET: DROC ANALYSIS 44
  • FIGURE 4 GLOBAL WHOLE EXOME SEQUENCING (WES) MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS 45
  • FIGURE 5 GLOBAL WHOLE EXOME SEQUENCING (WES) MARKET: COMPANY RESEARCH ANALYSIS 45
  • FIGURE 6 GLOBAL WHOLE EXOME SEQUENCING (WES) MARKET: INTERVIEW DEMOGRAPHICS 46
  • FIGURE 7 GLOBAL WHOLE EXOME SEQUENCING (WES) MARKET: MARKET APPLICATION COVERAGE GRID 48
  • FIGURE 8 GLOBAL WHOLE EXOME SEQUENCING (WES) MARKET: DBMR MARKET POSITION GRID 50
  • FIGURE 9 GLOBAL WHOLE EXOME SEQUENCING (WES) MARKET: VENDOR SHARE ANALYSIS 52
  • FIGURE 10 GLOBAL WHOLE EXOME SEQUENCING (WES) MARKET: SEGMENTATION 56
  • FIGURE 11 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE GLOBAL WHOLE EXOME SEQUENCING (WES) MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029 57
  • FIGURE 12 INCREASE IN USE OF WES TECHNOLOGY FOR NEW SCIENTIFIC APPLICATIONS AND INCREASING THE PREFERENCE OF WES OVER WHOLE-GENOME SEQUENCING IS ITS LOW-COST SEQUENCING CAPABILITY IS EXPECTED TO DRIVE THE GLOBAL WHOLE EXOME SEQUENCING (WES) MARKET IN THE FORECAST PERIOD OF 2022 TO 2029 58
  • FIGURE 13 THE INSTRUMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL WHOLE EXOME SEQUENCING (WES) MARKET IN 2022 & 2029 58
  • FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF THE GLOBAL WHOLE EXOME SEQUENCING MARKET 66
  • FIGURE 15 GLOBAL WHOLE EXOME SEQUENCING MARKET: BY COMPONENT, 2021 73
  • FIGURE 16 GLOBAL WHOLE EXOME SEQUENCING MARKET: BY COMPONENT, 2022-2029 (USD MILLION) 74
  • FIGURE 17 GLOBAL WHOLE EXOME SEQUENCING MARKET: BY COMPONENT, CAGR (2022-2029) 74
  • FIGURE 18 GLOBAL WHOLE EXOME SEQUENCING MARKET: BY COMPONENT, LIFELINE CURVE 75
  • FIGURE 19 GLOBAL WHOLE EXOME SEQUENCING MARKET: BY PRODUCT AND SERVICE, 2021 80
  • FIGURE 20 GLOBAL WHOLE EXOME SEQUENCING MARKET: BY PRODUCT AND SERVICE, 2022-2029 (USD MILLION) 81
  • FIGURE 21 GLOBAL WHOLE EXOME SEQUENCING MARKET: BY PRODUCT AND SERVICE, CAGR (2022-2029) 81
  • FIGURE 22 GLOBAL WHOLE EXOME SEQUENCING MARKET: BY PRODUCT AND SERVICE, LIFELINE CURVE 82
  • FIGURE 23 GLOBAL WHOLE EXOME SEQUENCING MARKET: BY APPLICATION, 2021 90
  • FIGURE 24 LOBAL WHOLE EXOME SEQUENCING MARKET: BY APPLICATION, 2022-2029 (USD MILLION) 91
  • FIGURE 25 GLOBAL WHOLE EXOME SEQUENCING MARKET: BY APPLICATION, CAGR (2022-2029) 91
  • FIGURE 26 GLOBAL WHOLE EXOME SEQUENCING MARKET: BY APPLICATION, LIFELINE CURVE 92
  • FIGURE 27 GLOBAL WHOLE EXOME SEQUENCING MARKET: BY END USER, 2021 98
  • FIGURE 28 GLOBAL WHOLE EXOME SEQUENCING MARKET: BY END USER, 2022-2029 (USD MILLION) 99
  • FIGURE 29 GLOBAL WHOLE EXOME SEQUENCING MARKET: BY END USER, CAGR (2022-2029) 99
  • FIGURE 30 GLOBAL WHOLE EXOME SEQUENCING MARKET: BY END USER, LIFELINE CURVE 100
  • FIGURE 31 GLOBAL WHOLE EXOME SEQUENCING MARKET: BY DISTRIBUTION CHANNEL, 2021 106
  • FIGURE 32 GLOBAL WHOLE EXOME SEQUENCING MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION) 107
  • FIGURE 33 GLOBAL WHOLE EXOME SEQUENCING MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029) 107
  • FIGURE 34 GLOBAL WHOLE EXOME SEQUENCING MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 108
  • FIGURE 35 GLOBAL WHOLE EXOME SEQUENCING MARKET: SNAPSHOT (2021) 114
  • FIGURE 36 GLOBAL WHOLE EXOME SEQUENCING MARKET: BY COUNTRY (2021) 115
  • FIGURE 37 GLOBAL WHOLE EXOME SEQUENCING MARKET: BY COUNTRY (2022 & 2029) 115
  • FIGURE 38 GLOBAL WHOLE EXOME SEQUENCING MARKET: BY COUNTRY (2021 & 2029) 116
  • FIGURE 39 GLOBAL WHOLE EXOME SEQUENCING MARKET: BY COMPONENT (2022-2029) 116
  • FIGURE 40 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET: SNAPSHOT (2021) 119
  • FIGURE 41 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET: BY COUNTRY (2021) 120
  • FIGURE 42 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET: BY COUNTRY (2022 & 2029) 120
  • FIGURE 43 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET: BY COUNTRY (2021 & 2029) 121
  • FIGURE 44 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET: BY COMPONENT (2022-2029) 121
  • FIGURE 45 EUROPE WHOLE EXOME SEQUENCING MARKET: SNAPSHOT (2021) 136
  • FIGURE 46 EUROPE WHOLE EXOME SEQUENCING MARKET: BY COUNTRY (2021) 137
  • FIGURE 47 EUROPE WHOLE EXOME SEQUENCING MARKET: BY COUNTRY (2022 & 2029) 137
  • FIGURE 48 EUROPE WHOLE EXOME SEQUENCING MARKET: BY COUNTRY (2021 & 2029) 138
  • FIGURE 49 EUROPE WHOLE EXOME SEQUENCING MARKET: BY COMPONENT (2022-2029) 138
  • FIGURE 50 ASIA-PACIFIC WHOLE EXOME SEQUENCING MARKET: SNAPSHOT (2021) 180
  • FIGURE 51 ASIA-PACIFIC WHOLE EXOME SEQUENCING MARKET: BY COUNTRY (2021) 181
  • FIGURE 52 ASIA-PACIFIC WHOLE EXOME SEQUENCING MARKET: BY COUNTRY (2022 & 2029) 181
  • FIGURE 53 ASIA-PACIFIC WHOLE EXOME SEQUENCING MARKET: BY COUNTRY (2021 & 2029) 182
  • FIGURE 54 ASIA-PACIFIC WHOLE EXOME SEQUENCING MARKET: BY COMPONENT (2022-2029) 182
  • FIGURE 55 SOUTH AMERICA WHOLE EXOME SEQUENCING MARKET: SNAPSHOT (2021) 230
  • FIGURE 56 SOUTH AMERICA WHOLE EXOME SEQUENCING MARKET: BY COUNTRY (2021) 231
  • FIGURE 57 SOUTH AMERICA WHOLE EXOME SEQUENCING MARKET: BY COUNTRY (2022 & 2029) 231
  • FIGURE 58 SOUTH AMERICA WHOLE EXOME SEQUENCING MARKET: BY COUNTRY (2021 & 2029) 232
  • FIGURE 59 SOUTH AMERICA WHOLE EXOME SEQUENCING MARKET: BY COMPONENT (2022-2029) 232
  • FIGURE 60 MIDDLE EAST AND AFRICA WHOLE EXOME SEQUENCING MARKET: SNAPSHOT (2021) 246
  • FIGURE 61 MIDDLE EAST AND AFRICA WHOLE EXOME SEQUENCING MARKET: BY COUNTRY (2021) 247
  • FIGURE 62 MIDDLE EAST AND AFRICA WHOLE EXOME SEQUENCING MARKET: BY COUNTRY (2022 & 2029) 247
  • FIGURE 63 MIDDLE EAST AND AFRICA WHOLE EXOME SEQUENCING MARKET: BY COUNTRY (2021 & 2029) 248
  • FIGURE 64 MIDDLE EAST AND AFRICA WHOLE EXOME SEQUENCING MARKET: BY COMPONENT (2022-2029) 248
  • FIGURE 65 GLOBAL WHOLE EXOME SEQUENCING MARKET: COMPANY SHARE 2021 (%) 271
  • FIGURE 66 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET: COMPANY SHARE 2021 (%) 272
  • FIGURE 67 EUROPE WHOLE EXOME SEQUENCING MARKET: COMPANY SHARE 2021 (%) 273
  • FIGURE 68 ASIA-PACIFIC WHOLE EXOME SEQUENCING MARKET: COMPANY SHARE 2021 (%) 274